Clicky

Titan Pharmaceuticals, Inc.(TTNP)

Description: Titan Pharmaceuticals, Inc., a specialty pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States. The company is developing Probuphine for the long term maintenance treatment of opioid dependence. Its Probuphine is designed to maintain a stable, around the clock blood level of the medicine buprenorphine in patients for six months following a single treatment; and utilizes ProNeura, a novel, proprietary, and long-term drug delivery technology. The company's ProNeura is also used in developing products for the treatment of other chronic conditions, such as Parkinson's disease. It is also developing Fanapt (iloperidone), an atypical antipsychotic for the treatment of schizophrenia. The company was founded in 1992 and is based in South San Francisco, California.


Keywords: Pharmaceutical Organic Compounds Chemical Compounds Parkinson's Disease Drug Delivery Schizophrenia Opioids Chronic Condition Morphinans Drug Rehabilitation Buprenorphine Treatment Of Schizophrenia Antipsychotic Drug Delivery Technology Atypical Antipsychotics Probuphine Fanapt Iloperidone Psychopathology Titan Pharmaceuticals

Home Page: www.titanpharm.com

TTNP Technical Analysis

400 Oyster Point Boulevard
South San Francisco, CA 94080-1958
United States
Phone: 650 244 4990


Officers

Name Title
Dr. Katherine L. Beebe-DeVarney Ph.D. Pres, COO & Director
Dr. Marc Rubin M.D. Exec. Director
Mr. David Elliot Lazar Principal Exec. Officer, Principal Financial Officer, CEO & Interim Chairman
Mr. Mike Fritz National Sales Director
Jennifer Kiernan Exec. Assistant to CEO & Investor Communications Coordinator
Joe Schrei Exec. Director of Commercial Operations

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 4.0385
Price-to-Sales TTM: 22.8021
IPO Date: 1996-01-18
Fiscal Year End: December
Full Time Employees: 11
Back to stocks